Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.

Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J.

Magn Reson Med. 2008 Sep;60(3):510-6. doi: 10.1002/mrm.21694.

2.

Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.

Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J.

Cancer Res. 2008 Oct 15;68(20):8607-15. doi: 10.1158/0008-5472.CAN-08-0749.

3.

Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy.

Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG.

NMR Biomed. 2010 May;23(4):391-8. doi: 10.1002/nbm.1474. Epub 2009 Dec 23.

4.

Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.

Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J.

Magn Reson Med. 2006 Jun;55(6):1257-64.

5.

High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies.

van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A.

MAGMA. 2008 Nov;21(6):435-42. doi: 10.1007/s10334-008-0156-9. Epub 2008 Nov 25.

PMID:
19031091
6.

The role of metabolic imaging in radiation therapy of prostate cancer.

Zhang VY, Westphalen A, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J.

NMR Biomed. 2014 Jan;27(1):100-11. doi: 10.1002/nbm.3007. Epub 2013 Aug 12. Review.

7.

In vivo (1) H MR spectroscopic imaging of aggressive prostate cancer: can we detect lactate?

Kobus T, Wright AJ, Van Asten JJ, Heerschap A, Scheenen TW.

Magn Reson Med. 2014 Jan;71(1):26-34. doi: 10.1002/mrm.24635. Epub 2013 Mar 8.

PMID:
23475759
8.

Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate.

Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J.

Magn Reson Med. 2009 Nov;62(5):1091-8. doi: 10.1002/mrm.22120.

9.

Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.

Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J.

Magn Reson Med. 2008 Jul;60(1):33-40. doi: 10.1002/mrm.21647.

10.

The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.

Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, Fraser C, Kurban L, Lam TB, Padhani AR, Royle J, Scheenen TW, Tassie E.

Health Technol Assess. 2013 May;17(20):vii-xix, 1-281. doi: 10.3310/hta17200. Review.

11.

Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Keshari KR, Sriram R, Van Criekinge M, Wilson DM, Wang ZJ, Vigneron DB, Peehl DM, Kurhanewicz J.

Prostate. 2013 Aug;73(11):1171-81. doi: 10.1002/pros.22665. Epub 2013 Mar 26.

12.

Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.

Kuru TH, Roethke MC, Seidenader J, Simpfendörfer T, Boxler S, Alammar K, Rieker P, Popeneciu VI, Roth W, Pahernik S, Schlemmer HP, Hohenfellner M, Hadaschik BA.

J Urol. 2013 Oct;190(4):1380-6. doi: 10.1016/j.juro.2013.04.043. Epub 2013 Apr 19.

PMID:
23608676
13.
14.

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

Giskeødegård GF, Bertilsson H, Selnæs KM, Wright AJ, Bathen TF, Viset T, Halgunset J, Angelsen A, Gribbestad IS, Tessem MB.

PLoS One. 2013 Apr 23;8(4):e62375. doi: 10.1371/journal.pone.0062375. Print 2013.

15.

Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report.

Narayan P, Jajodia P, Kurhanewicz J, Thomas A, MacDonald J, Hubesch B, Hedgcock M, Anderson CM, James TL, Tanagho EA, et al.

J Urol. 1991 Jul;146(1):66-74.

PMID:
1711587
16.

Magnetic resonance imaging-targeted, 3D transrectal ultrasound-guided fusion biopsy for prostate cancer: Quantifying the impact of needle delivery error on diagnosis.

Martin PR, Cool DW, Romagnoli C, Fenster A, Ward AD.

Med Phys. 2014 Jul;41(7):073504. doi: 10.1118/1.4883838.

PMID:
24989418
17.

Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy.

Rastinehad AR, Turkbey B, Salami SS, Yaskiv O, George AK, Fakhoury M, Beecher K, Vira MA, Kavoussi LR, Siegel DN, Villani R, Ben-Levi E.

J Urol. 2014 Jun;191(6):1749-54. doi: 10.1016/j.juro.2013.12.007. Epub 2013 Dec 12.

PMID:
24333515
19.

Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue.

De Silva SS, Payne GS, Thomas V, Carter PG, Ind TE, deSouza NM.

NMR Biomed. 2009 Feb;22(2):191-8. doi: 10.1002/nbm.1302.

PMID:
18833545
20.

Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit?

Acar Ö, Esen T, Çolakoğlu B, Vural M, Onay A, Sağlıcan Y, Türkbey B, Rozanes İ.

Diagn Interv Radiol. 2015 Jul-Aug;21(4):271-6. doi: 10.5152/dir.2015.46014.

Supplemental Content

Support Center